Inhibikase reports Q3 2026 results, updates IMPROVE-PAH Phase 3 progress for IKT-001
The company said 79 of a planned 180 trial sites are activated across 28 countries, with an interim safety readout for Part A expected in the first half of 2027.
SEC filing